SCHEMBL2297946

SCHEMBL2297946

Cc1ccc(Br)cc1NC(=O)c1ccccc1C(=O)c1ccc2nc(NC(=O)O)[nH]c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 5/20 0.57
▸ BRAF P15056 5/20 0.57
▸ ALDH1A1 P00352 4/20 0.50
▸ ABL1 P00519 3/20 0.50
▸ CYP2C9 P11712 3/20 0.50
▸ LMNA P02545 2/20 0.50
▸ HTT P42858 2/20 0.50
▸ CYP1A2 P05177 2/20 0.50
▸ ABCC4 O15439 1/20 0.50
▸ USP2 O75604 1/20 0.50
▸ KDR P35968 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ MAPT P10636 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.49
▸ XIAP P98170 1/20 0.48
▸ CYP2C19 P33261 2/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2297867 0.90 RAF1 (0.54) RAF1BRAFALDH1A1ABL1CYP2C9
SCHEMBL2301152 0.89 RAF1 (0.57) RAF1BRAFALDH1A1ABL1CYP2C9
SCHEMBL1469017 0.85 ALDH1A1 (0.47) RAF1BRAFALDH1A1ABL1CYP2C9
SCHEMBL2356348 0.85 RAF1 (0.59) RAF1BRAFALDH1A1ABL1CYP2C9
SCHEMBL2358832 0.82 RAF1 (0.54) RAF1BRAFALDH1A1ABL1CYP2C9
SCHEMBL2357595 0.82 RAF1 (0.56) RAF1BRAFALDH1A1ABL1CYP2C9
SCHEMBL2300130 0.81 RAF1 (0.57) RAF1BRAFALDH1A1ABL1CYP2C9
SCHEMBL3031368 0.80 RAF1 (0.81) RAF1BRAFALDH1A1ABL1CYP2C9
SCHEMBL2357955 0.80 RAF1 (0.63) RAF1BRAFALDH1A1ABL1CYP2C9
SCHEMBL2299028 0.79 RAF1 (0.57) RAF1BRAFALDH1A1ABL1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
EP-2139484-B9 METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA EXELIXIS INC (US) 2014-06-11 — — EP disclosed
EP-2139483-B9 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2014-05-21 — — EP disclosed
EP-2139483-B1 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2013-09-18 — — EP disclosed
EP-2139484-B1 METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA EXELIXIS INC (US) 2013-07-17 — — EP disclosed
US-7999006-B2 Anticancer agents; mitogen-activated protein kinases (MEK) EXELIXIS, INC. (US) 2011-08-16 — — US disclosed
Send feedback